Bibliografía del artículo
1. Curry CJ, Estevenson RE, Aughton D y col. Evaluation of mental retardation: Recommendations of a consensus conference. Am J Med Genet 72:468-477, 1997.
2. Basel-Vanagaite L. Genetics of autosomal recessive non-syndromic mental retardation: recent advances. Clin Genet; 72(3):167-74, 2007.
3. Van Karnebeek CDM, Jansweijer MCE, Leenders AGE, Offringa M, Hennekam. Diagnostic investigation in individuals with mental retardation: a systematic literature review of their usefulness. Eur J Hum Genet 13:6-25, 2005.
4. Rodríguez-Revenga L, Madrigal-Bajo I, Milà-Racasens M. Genetic mental retardation. Rev Neurol 43(Suppl 1):S181-6, 2003.
5. Flint J, Knight S. The use of telomere probes to investigate submicroscopic rearrangements associated with mental retardation. Curr Opin Genet Dev 13(3):310-6, 2003.
6. Raymond FL, Tarpey P. The genetics of mental retardation. Hum Mol Genet 15(Spec No 2):R110-6, 2006.
7. Rehder H, Fritz B. Genetic causes of mental retardation. Wien Med Wochenschr 155:248-267, 2005.
8. Migaud M, Charlesworth P, Dempster M y col. Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein. Nature 396(6710):433-9, 1998.
9. Zahir F, Friedman JM. The impact of array genomic hybridization on mental retardation research: a review of current technologies and their clinical utility. Clin Genet 72(4):271-87, 2007.
10. Lee MJ, Stephenson DA. Recent developments in neurofibromatosis type 1. Curr Opin Neurol 20(2):135-41, 2007.
11. Ozonoff S. Cognitive impairment in neurofibromatosis type 1. Am J Med Genet 89:45-52, 1999.
12. Radtke HB, Sebold CD, Allison C, Haidle JL, Schneider G. Neurofibromatosis type 1 in genetic counseling practice: recommendations of the National Society of Genetic Counselors. J Genet Couns 16(4):387-407, 2007.
13. Huson SM, Hughes RAC. The neurofibromatoses: a pathogenetic and clinical overview. Chapman & Hall Medical, London 1994.
14. Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 111:1355-1381, 1988.
15. Riccarddi VM. Neurofibromatosis: phenotype, natural history and pathogenesis. Johns Hopkins University Press, Baltimore, 1992.
16. Ferner RE. Neurofibromatosis 1. Eur J Hum Genet 15(2):131-8, 2007.
17. Moore BD, Slopis JM, Schomer D, Jackson EF, Levy BM. Neuropsychological significance of areas of high signal intensity on brain MRIs of children with neurofibromatosis. Neurology 46:1660-1668, 1996.
18. Ferner RE, Huson SM, Thomas N y col. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44(2):81-8, 2007.
19. Schindeler A, Little DG. Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Bone 42(4):616-22, 2008.
20. Grisart B, Rack K, Vidrequin S y col. NF1 microduplication first clinical report: association with mild mental retardation, early onset of baldness and dental enamel hypoplasia? Eur J Hum Genet 16(3):305-11, 2008.
21. Dorschner MO, Sybert VP, Weaver M, Pletcher BA, Stephens K. NF1 microdeletion breakpoints are clustered at flanking repetitive sequences. Hum Mol Genet 9:35-46, 2000.
22. Mulvihill JJ. Neurofibromatosis. A genetic epidemiologist's point of view. Ann N Y Acad Sci 486:38-44, 1986.
23. Cawthon RM, Weiss R, Xu GF y col. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62:193-201, 1990.
24. Viskochil D, Buchberg AM, Xu G y col. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62:187-192, 1990.
25. Wallace MR, Andersen LB, Saulino AM, Gregory PE, Glover TW, Collins FS. A de novo Alu insertion results in neurofibromatosis type 1. Nature 353:864-866, 1991.
26. Yohay KH. The genetic and molecular pathogenesis of NF1 and NF2. Semin Pediatr Neurol 13(1):21-6, 2006.
27. Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol 6(4):340-51, 2007.
28. Costa RM, Silva AJ. Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1. J Child Neurol 17:622-626, 2002.
29. Hsueh YP. Neurofibromin signaling and synapses. J Biomed Sci 14(4):461-6, 2007.
30. Holmes GL, Stafstrom CE; Tuberous Sclerosis Study Group. Tuberous sclerosis complex and epilepsy: recent developments and future challenges. Epilepsia 48(4):617-30, 2007.
31. Sampson JR. TSC1 and TSC2: genes that are mutated in the human genetic disorder tuberous sclerosis. Bioch Soc Transac 31:592-596, 2003.
32. Schwartz RA, Fernández G, Kotulska K, Jó?wiak S.Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 57(2):189-202, 2007.
33. Leung AK, Robson WL. Tuberous sclerosis complex: a review. J Pediatr Health Care 21(2):108-14, 2007.
34. Bernstein J. Renal cystic disease in tuberous sclerosis complex. Pediatr Nephrol 7:490-495, 1993.
35. Moss J, Avila NA, Barnes PM y col. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 163:669-671, 2001.
36. Fryer AE, Chalmers A, Connor JM y col. Evidence that the gene for tuberous sclerosis is on chromosome 9. Lancet I:659-661, 1987.
37. Kandt RS, Haines JL, Smith M y col. Linkage of an important gene locus for tuberous sclerosis to a chomosome 16 marker for polycystic kidney disease. Nat Genet 2:37-41, 1992.
38. Cheadle JP, Reeve MP, Sampson JR, Kwiatkowski DJ. Molecular genetic advances in tuberous sclerosis. Hum Genet 107:97-114, 2000.
39. Yates JR. Tuberous sclerosis. Eur J Hum Genet 14(10):1065-73, 2006.
40. Sampson JR, Maheshwar MM, Aspinwall R y col. Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene. Am J Hum Genet 61:843-851, 1997.
41. Van Slegtenhorst M, De Hoogt R, Hermans C y col. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 77:805-808, 1997.
42. Carbonara C, Longa L, Grosso E y col. Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal regions in tuberous sclerosis hamartomas. Genes Chromosom Cancer 15:18-25, 1996.
43. De Vries PJ, Howe CJ. The tuberous sclerosis complex proteins--a GRIPP on cognition and neurodevelopment. Trends Mol Med 13(8):319-26, 2007.
44. Meikle L, Pollizzi K, Egnor A y col. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 28(21):5422-32, 2008.
45. Ehninger D, Han S, Shilyansky C y col. Reversal of learning deficits in a Tsc2(+/-) mouse model of tuberous sclerosis. Nat Med [Epub ahead of print] 2008.
46. Franz DN, Leonard J, Tudor C y col. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59(3):490-8, 2006.
47. Meola G. Clinical and genetic heterogeneity in myotonic dystrophies. Muscle Nerve 23:1789-1799, 2000.
48. Schara U, Schoser BG. Myotonic dystrophies type 1 and 2: a summary on current aspects. Semin Pediatr Neurol 13(2):71-9, 2006.
49. Brook JD, McCurrach ME, Harley HG y col. Molecular basis of myotonic dystrophy: expansion of trinucleotide (CTG) repeat at the 3' end of a transcription encoding a protein kinase family member. Cell 68:799-808, 1992.
50. Harley HG, Rundle SA, MacMillan JC y col. Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy. Am J Hum Genet 52:1164-1174, 1993.
51. Hamshere MG, Harley H, Harper P, Brook JD, Brookfield JF. Myotonic dystrophy: the correlation of (CTG) repeat length in leucocytes with age at onset is significant only for patients with small expansions. J Med Genet 36:59-61, 1999.
52. Ashizawa T, Dubel JR, Harati Y. Somatic instability of CTG repeat in myotonic dystrophy. Neurology 43:2674-2678, 1993.
53. Monckton DG, Wong LJ, Ashizawa T, Caskey CT. Somatic mosaicism, germline expansions, germline reversions and intergenerational reductions in myotonic distrophy males: small pool PCR. Hum Mol Genet 4:1-8, 1995.
54. Gatchel JR, Zoghbi HY. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet 6(10):743-55, 2005.
55. Cho DH, Tapscott SJ. Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Biochim Biophys Acta 1772(2):195-204, 2007.
56. Perez E, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge and velocardiofacial syndromes). Curr Opin Pediatr 14(6):678-83, 2002.
57. Hay BN. Deletion 22q11: spectrum of associated disorders. Semin Pediatr Neurol 14(3):136-9, 2007.
58. Greenberg F. DiGeorge syndrome: an historical review of clinical and cytogenetic features. J Med Genet 30(10):803-6, 1993.
59. Dodson WE, Alexander D, Al-Aish M, De la Cruz F. The DiGeorge syndrome. Lancet 1(7594):574-5, 1969.
60. Knight SJ, Regan R, Nicod A y col. Subtle chromosomal rearrangements in children with unexplained mental retardation. Lancet 354:1676-1681, 1999.
61. Slavotinek A, Rosenberg M, Knight S y col. Screening for submicroscopic chromosome rearrangements in children with idiopathic mental retardation using microsatellite markers for the chromosome telomeres. J Med Genet 36:405-411, 1999.
62. Ravnan JB, Tepperberg JH, Papenhausen P y col. Subtelomere FISH analysis of 11 688 cases: an evaluation of the frequency and pattern of subtelomere rearrangements in individuals with developmental disabilities. J Med Genet 43:478-489, 2006.
63. Krepischi-Santos AC, Vianna-Morgante AM, Jehee FS y col. Whole-genome array-CGH screening in undiagnosed syndromic patients: old syndromes revisited and new alterations. Cytogenet Genome Res 115(3-4):254-61, 2006.
64. Friedman JM, Baross A, Delaney AD y col. Oligonucleotide microarray analysis of genomic imbalance in children with mental retardation. Am J Hum Genet 79(3):500-13, 2006.
65. Menten B, Maas N, Thienpont B y col. Emerging patterns of cryptic chromosomal imbalance in patients with idiopathic mental retardation and multiple congenital anomalies: a new series of 140 patients and review of published reports. J Med Genet 43(8):625-33, 2006.
66. Miyake N, Shimokawa O, Harada N y col. BAC array CGH reveals genomic aberrations in idiopathic mental retardation. Am J Med Genet A 140(3):205-11, 2006.
67. Rosenberg C, Knijnenburg J, Bakker E y col. Array-CGH detection of micro rearrangements in mentally retarded individuals: clinical significance of imbalances present both in affected children and normal parents. J Med Genet 43(2):180-6, 2006.
68. De Vries BB, Pfundt R, Leisink M y col. Diagnostic genome profiling in mental retardation. Am J Hum Genet 77(4):606-16, 2005.
69. Shaw-Smith C, Redon R, Rickman L y col. Microarray based comparative genomic hybridisation (array-CGH) detects submicroscopic chromosomal deletions and duplications in patients with learning disability/mental retardation and dysmorphic features. J Med Genet 41(4):241-8, 2004.
70. Vissers LE, De Vries BB, Osoegawa K y col. Array-based comparative genomic hybridization for the genomewide detection of submicroscopic chromosomal abnormalities. Am J Hum Genet 73(6):1261-70, 2003.
71. Schoumans J, Ruivenkamp C, Holmberg E, Kyllerman M, Anderlid BM, Nordenskjöld M. Detection of chromosomal imbalances in children with idiopathic mental retardation by array based comparative genomic hybridisation (array-CGH). J Med Genet 42(9):699-705, 2005.
72. Tyson C, Harvard C, Locker R y col. Submicroscopic deletions and duplications in individuals with intellectual disability detected by array-CGH. Am J Med Genet A 139(3):173-85, 2005.